Edition:
United States

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

7.03USD
3:59pm EST
Change (% chg)

$-0.01 (-0.14%)
Prev Close
$7.04
Open
$6.96
Day's High
$7.65
Day's Low
$6.96
Volume
18,300
Avg. Vol
20,135
52-wk High
$15.70
52-wk Low
$5.28

Latest Key Developments (Source: Significant Developments)

Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome
Wednesday, 20 Dec 2017 08:00am EST 

Dec 20 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME.OVID THERAPEUTICS INC - CURRENTLY EVALUATING PHASE 1B/2A CLINICAL TRIAL OF TAK-935/OV935 WITH DATA ANTICIPATED IN 2018.  Full Article

Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME.OVID THERAPEUTICS INC - EXPANDED ONGOING PHASE 2 STARS CLINICAL TRIAL TO INCLUDE BOTH ADULTS AND ADOLESCENTS WITH ANGELMAN SYNDROME.OVID THERAPEUTICS INC - EXPECTS DATA FROM STARS TRIAL IN SECOND HALF OF 2018.  Full Article

Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome
Tuesday, 5 Dec 2017 08:00am EST 

Dec 5 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME.OVID THERAPEUTICS INC - HAVE RAPIDLY ADVANCED TAK-935/OV935 PROGRAM INTO A PHASE 1B/2A CLINICAL TRIAL AND ANTICIPATE DATA IN 2018.  Full Article

Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients
Tuesday, 28 Nov 2017 04:00pm EST 

Nov 28 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS.OVID THERAPEUTICS INC - ‍ANTICIPATES DATA FROM STARS TRIAL TO BE AVAILABLE IN SECOND HALF OF 2018​.OVID THERAPEUTICS INC - ‍RESULTS FROM PHASE 1 CLINICAL TRIAL OF ADOLESCENTS WITH ANGELMAN AND FRAGILE X SYNDROMES DEMONSTRATED OV101 WAS WELL TOLERATED​.OVID THERAPEUTICS INC - ‍IN TRIAL, OV101 WAS FOUND TO BE GENERALLY SAFE AND WELL TOLERATED​.  Full Article

Ovid Therapeutics Q3 loss per share $0.38
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Ovid Therapeutics Inc ::Ovid Therapeutics reports third quarter 2017 financial results and corporate progress.Q3 loss per share $0.38.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Ovid Therapeutics Inc - ‍cash and cash equivalents $96 million as at Sept 30 , 2017 versus $51.9 million as at Dec 31, 2016​.  Full Article

Ovid Therapeutics Q2 loss per share $0.57
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Ovid Therapeutics Inc :Ovid Therapeutics reports second quarter 2017 financial results and corporate progress.Q2 loss per share $0.57.Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.  Full Article

Ovid Therapeutics shares open at $14.00 in debut, 6.7 pct below IPO price
Friday, 5 May 2017 10:31am EDT 

May 5 (Reuters) - :Ovid Therapeutics Inc shares open at $14.00 in debut, below IPO price of $15.00 per share.  Full Article

Ovid Therapeutics prices 5 mln share offering at $15 per share
Thursday, 4 May 2017 06:20pm EDT 

May 4 (Reuters) - Ovid Therapeutics Inc ::Ovid Therapeutics announces pricing of initial public offering.Says initial public offering of 5 million common shares priced at $15 per share.  Full Article

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME